Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + cytarabine + dexamethasone + pegteograstim
- Development stage
- Unknown
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
A combination therapy regimen consisting of bortezomib (a proteasome inhibitor), cytarabine (an antineoplastic agent), dexamethasone (a corticosteroid), and pegteograstim (a granulocyte colony-stimulating factor). This combination is used in the treatment of hematological malignancies, particularly mantle cell lymphoma.
02
Targets
GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)CSF3R (Granulocyte colony-stimulating factor receptor)DNA polymerase family
Beyond the preview
Go deeper on bortezomib + cytarabine + dexamethasone + pegteograstim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + cytarabine + dexamethasone + pegteograstim.